Login to Your Account

Speedel Begins Pivotal Trial Of SPP301 In Diabetic Nephropathy

By Jennifer Boggs

Wednesday, July 13, 2005
Four months after reporting positive results from a Phase IIb trial of its endothelin A receptor antagonist, SPP301, in diabetic nephropathy, Speedel Group AG initiated a pivotal Phase III study in Type II diabetes patients. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription